JP2018508208A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508208A5
JP2018508208A5 JP2017543737A JP2017543737A JP2018508208A5 JP 2018508208 A5 JP2018508208 A5 JP 2018508208A5 JP 2017543737 A JP2017543737 A JP 2017543737A JP 2017543737 A JP2017543737 A JP 2017543737A JP 2018508208 A5 JP2018508208 A5 JP 2018508208A5
Authority
JP
Japan
Prior art keywords
antibodies
isolated
recombinant
agents
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017543737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018508208A (ja
JP6987638B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/075583 external-priority patent/WO2016131503A1/en
Publication of JP2018508208A publication Critical patent/JP2018508208A/ja
Publication of JP2018508208A5 publication Critical patent/JP2018508208A5/ja
Priority to JP2021194395A priority Critical patent/JP2022058341A/ja
Application granted granted Critical
Publication of JP6987638B2 publication Critical patent/JP6987638B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017543737A 2015-02-17 2015-11-03 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体 Expired - Fee Related JP6987638B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021194395A JP2022058341A (ja) 2015-02-17 2021-11-30 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15155448.2 2015-02-17
EP15155448 2015-02-17
PCT/EP2015/075583 WO2016131503A1 (en) 2015-02-17 2015-11-03 Antibodies targeting a galactan-based o-antigen of k. pneumoniae

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194395A Division JP2022058341A (ja) 2015-02-17 2021-11-30 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体

Publications (3)

Publication Number Publication Date
JP2018508208A JP2018508208A (ja) 2018-03-29
JP2018508208A5 true JP2018508208A5 (https=) 2019-04-18
JP6987638B2 JP6987638B2 (ja) 2022-01-05

Family

ID=52469764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017543737A Expired - Fee Related JP6987638B2 (ja) 2015-02-17 2015-11-03 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体
JP2021194395A Withdrawn JP2022058341A (ja) 2015-02-17 2021-11-30 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021194395A Withdrawn JP2022058341A (ja) 2015-02-17 2021-11-30 クレブシエラ・ニューモニエのガラクタンベースのｏ抗原をターゲティングする抗体

Country Status (12)

Country Link
US (2) US11466074B2 (https=)
EP (1) EP3259287A1 (https=)
JP (2) JP6987638B2 (https=)
KR (1) KR20170122726A (https=)
CN (1) CN107371365B (https=)
AU (1) AU2015383632B2 (https=)
BR (1) BR112017017553A2 (https=)
CA (1) CA2973134A1 (https=)
IL (1) IL253920B2 (https=)
MX (1) MX2017009955A (https=)
RU (2) RU2021131224A (https=)
WO (1) WO2016131503A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?
KR20190077306A (ko) 2016-08-05 2019-07-03 메디뮨 엘엘씨 항-o2 항체 및 이의 용도
SG11201903063UA (en) * 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN120775040A (zh) * 2021-08-25 2025-10-14 北京三诺佳邑生物技术有限责任公司 特异性识别肺炎克雷伯菌o1抗原的抗体及其应用
EP4445911A4 (en) 2021-12-06 2025-10-22 Beijing Solobio Genetechnology Co Ltd BISPECIFIC ANTIBODY THAT BINDS SPECIFICALLY TO KLEBSIELLA PNEUMONIAE O1 AND O2 ANTIGENS AND COMPOSITION
CN118620072A (zh) * 2023-12-27 2024-09-10 上海博钒生物科技有限公司 一种肺炎克雷伯菌多糖单克隆抗体、其杂交瘤细胞株及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20050112141A1 (en) * 2000-08-30 2005-05-26 Terman David S. Compositions and methods for treatment of neoplastic disease
EA013564B1 (ru) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
BR112017017553A2 (pt) * 2015-02-17 2018-05-08 Arsanis Biosciences Gmbh ?anticorpos direcionados contra um antígeno o baseado em galactano de k. pneumoniae, método de produção, preparação farmacêutica ou diagnóstica, método de diagnóstico, método de identificação, ácido nucleico isolado, célula hospedeira e invólucro de expressão?

Similar Documents

Publication Publication Date Title
JP2018508208A5 (https=)
ES2341461T5 (es) Procedimientos de tratamiento de la artrosis con anticuerpos ANTI-IL-6
US10233234B2 (en) Binding moieties for biofilm remediation
US20240000971A1 (en) Compositions and methods for the treatment of tauopathy
BR112021003410A2 (pt) anticorpos de domínio único anti-bcma, grupo de genes dos ditos anticorpos, polipeptídeo, vetor de expressão, célula hospedeira, receptor de antígeno quimérico, célula t modificada pelo mesmo, composição farmacêutica e usos dos ditos anticorpos
UA119320C2 (uk) Активуюча т-клітини біспецифічна антигензв'язувальна молекула
Miersch et al. Intracellular targeting with engineered proteins
TWI859623B (zh) Il10單體融合蛋白及其應用
US20210139569A1 (en) Antibody binding active alpha-synuclein
Olga et al. Nanobodies are potential therapeutic agents for the Ebola virus infection
TW202126684A (zh) 抗α-溶血素的抗體及其應用
CN109414426A (zh) 使用精氨酸耗竭剂的组合癌症免疫疗法
JP2019524851A (ja) がんを治療するための組み合わせ
KR20250004742A (ko) 자궁내막증 및 다른 양성 부인과 신생물의 치료를 위한 제제
US9683042B2 (en) T-cell-specific humanized single fragment antibody delivery vehicle
Li et al. Canine distemper virus (CDV)-neutralizing activities of an anti-CDV canine-derived single-chain variable antibody fragment 4-15 (scFv 4-15) screened by phage display technology
US20200330591A1 (en) Treatment
CN116832177A (zh) 干扰趋化素样因子超家族成员6(cmtm6)表达的基因治疗载体的制备和抗肿瘤应用
AU2015258996A1 (en) Diagnostic test and treatment/prevention of alzheimer's disease
JP2020501518A (ja) キメラタンパク質を用いたアレルギー疾患の治療
JP6479331B2 (ja) 脊髄組織標的化ペプチド及びその利用
WO2024020236A2 (en) Monoclonal antibodies that interfere with iron uptake
US20230391861A1 (en) Potent binding agents for activation of the hedgehog signaling pathway
US20080233120A1 (en) Anti-p53 Antibodies
WO2006070290A2 (en) Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders